Loading... Please wait... Loading... Please wait...
ESTIMATED
03/28/2024
03/28/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.42 | -$0.41 | -$0.41 |
| Q2 2024 | 1 | -$0.39 | -$0.39 | -$0.39 |
| Q3 2024 | 0 | -$0.35 | -$0.35 | -$0.35 |
| Q4 2024 | 0 | -$0.35 | -$0.35 | -$0.35 |
Can-Fite BioPharma Ltd. last posted its earnings results on Thursday, March 28th, 2024. The company reported $-0.31 earnings per share for the quarter, missing analysts' consensus estimates of $-0.27 by $0.04. The company had revenue of 155,000 for the quarter and had revenue of 743,000 for the year. Can-Fite BioPharma Ltd. has generated $-2 earnings per share over the last year ($-1.79 diluted earnings per share) and currently has a price-to-earnings ratio of -1.47. Can-Fite BioPharma Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, July 7th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/28/2024 | Q4 2023 | -$0.27 | -$0.36 | -0.09 | $200,000 | $155,000 | 11/30/2023 | Q3 2023 | -$0.43 | -$0.44 | -0.01 | $200,000 | $196,000 | 06/01/2023 | Q2 2023 | -$1.52 | -$0.41 | 1.11 | $200,000 | $196,000 | 03/31/2023 | Q1 2023 | -$0.61 | $196,000 | 03/30/2023 | Q4 2022 | -$0.57 | -$1.09 | -0.52 | $500,000 | $197,000 | 11/25/2022 | Q3 2022 | -$1.00 | -$0.00 | 1 | $300,000 | $204,000 | 06/29/2022 | Q2 2022 | -$0.00 | $250,000 | $204,000 | 03/24/2022 | Q1 2022 | -$1.80 | -$0.00 | 1.8 | $205,000 | 03/24/2022 | Q4 2021 | -$1.80 | -$0.01 | 1.79 | $204,000 | 11/26/2021 | Q3 2021 | -$1.00 | -$0.01 | 0.99 | $140,000 | $251,000 | 06/29/2021 | Q2 2021 | -$0.01 | $218,333 | $250,000 | 03/25/2021 | Q1 2021 | -$1.30 | -$0.00 | 1.3 | $148,000 | 03/25/2021 | Q4 2020 | -$1.30 | -$0.01 | 1.29 | $150,000 | 11/30/2020 | Q3 2020 | -$2.50 | -$0.01 | 2.49 | $500,000 | $211,000 | 06/29/2020 | Q2 2020 | -$0.01 | $250,000 | $204,000 | 03/31/2020 | Q1 2020 | -$0.02 | $198,000 | 03/27/2020 | Q4 2019 | -$8.90 | -$0.01 | 8.89 | $192,000 | 11/29/2019 | Q3 2019 | -$5.80 | -$0.03 | 5.77 | $1.15 M | 06/29/2019 | Q2 2019 | -$0.04 | $295,249 | $389,000 | 03/31/2019 | Q1 2019 | -$0.04 | $299,000 |
|---|
A. Can-Fite BioPharma Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, July 7th, 2024 based off last year's report dates.
A. The conference call for Can-Fite BioPharma Ltd.'s latest earnings report can be listened to online.
A. The conference call transcript for Can-Fite BioPharma Ltd.'s latest earnings report can be read online.
A. Can-Fite BioPharma Ltd. (AMEX:CANF) has a recorded annual revenue of $743,000.
A. Can-Fite BioPharma Ltd. (AMEX:CANF) has a recorded net income of $743,000. Can-Fite BioPharma Ltd. has generated $-1.79 earnings per share over the last four quarters.
A. Can-Fite BioPharma Ltd. (AMEX:CANF) has a price-to-earnings ratio of -1.47 and price/earnings-to-growth ratio is -0.03.
